T. Rowe Price Investment Management Inc. Buys 431,178 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

T. Rowe Price Investment Management Inc. grew its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 43.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,415,179 shares of the company's stock after buying an additional 431,178 shares during the quarter. T. Rowe Price Investment Management Inc. owned approximately 2.23% of Vera Therapeutics worth $59,848,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Avoro Capital Advisors LLC boosted its holdings in Vera Therapeutics by 30.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock valued at $237,247,000 after acquiring an additional 1,300,410 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Vera Therapeutics by 11.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company's stock valued at $185,107,000 after purchasing an additional 437,940 shares in the last quarter. FMR LLC increased its position in shares of Vera Therapeutics by 9.6% during the fourth quarter. FMR LLC now owns 3,053,126 shares of the company's stock valued at $129,117,000 after buying an additional 267,842 shares during the period. Vanguard Group Inc. increased its position in shares of Vera Therapeutics by 14.3% during the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company's stock valued at $124,737,000 after buying an additional 369,387 shares during the period. Finally, Geode Capital Management LLC raised its stake in Vera Therapeutics by 14.8% in the fourth quarter. Geode Capital Management LLC now owns 1,153,325 shares of the company's stock worth $48,787,000 after buying an additional 148,660 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. The Goldman Sachs Group started coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price objective on the stock. Guggenheim upped their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. JPMorgan Chase & Co. lowered their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research report on Tuesday, March 4th. Finally, Wolfe Research started coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $64.67.

Vera Therapeutics Stock Down 1.6 %

NASDAQ:VERA traded down $0.39 on Thursday, reaching $22.99. 220,917 shares of the stock traded hands, compared to its average volume of 744,315. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -8.80 and a beta of 1.28. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $51.61. The company's fifty day simple moving average is $24.93 and its 200 day simple moving average is $35.56.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.11. Equities analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.